Browse by author
Lookup NU author(s): Dr Jess Dyson, Professor Chris Day
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of chronic liver disease in developed countries. Treatment depends on the stage of disease, and noninvasive methods for risk stratification are urgently needed. Lifestyle modification (aimed at weight loss and increasing physical activity) and management of the features of metabolic syndrome are vital for all patients with NAFLD. Metformin is the first-line therapy for diabetic patients with NAFLD and also reduces the risk of hepatocellular carcinoma. Clinicians should have a low threshold for introducing a statin for the management of dyslipidaemia. Antihypertensive agents that target the renin-angiotensin system should be first-line in NAFLD for the management of hypertension. For patients with progressive disease, liver-directed pharmacotherapy with vitamin E should be considered. Non-alcoholic steatohepatitis cirrhosis is an increasingly common indication for liver transplantation. ©
Author(s): Dyson JK, Day CP
Publication type: Article
Publication status: Published
Journal: Digestive Diseases
Year: 2014
Volume: 32
Issue: 5
Pages: 597-604
Print publication date: 01/07/2014
Acceptance date: 01/07/2014
ISSN (print): 0257-2753
ISSN (electronic): 1421-9875
Publisher: S. Karger AG
URL: https://doi.org/10.1159/000360511
DOI: 10.1159/000360511
Altmetrics provided by Altmetric